DEVELOPMENT OF ANTIVIRALS FOR SPECIFIC RNA VIRAL FAMILIES OF PANDEMIC POTENTIAL

针对具有大流行潜力的特定 RNA 病毒家族开发抗病毒药物

• 批准号: 10933177
• 负责人: GREG HENKEL
• 金额: $ 369.2万
• 依托单位: ARISAN THERAPEUTICS, INC.
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-09-22 至 2025-12-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10933177
• 关键词: Advanced Development; Chemistry; Clinical; Development; Family; Lassa virus; Pathway interactions; RNA; Viral; Virus; antiviral drug development; efficacy evaluation; manufacture; pandemic disease; pandemic potential; pre-clinical; product development; programs; research and development; safety assessment; therapeutic candidate; therapeutic development

To support the advanced development of a promising candidate therapeutic for a virus with pandemic potential included under the Antiviral Program for Pandemics. The research and development activities to be supported will allow the candidate therapeutic product to progress through the product development pathway, and include preclinical and IND enabling development activities, chemistry optimization/development, GMP manufacturing, and clinical safety and efficacy assessment.

支持对大流行抗病毒计划中有大流行潜力的病毒进行有前途的候选治疗药物的高级开发。支持的研发活动将允许候选治疗产品通过产品开发途径取得进展，包括临床前和IND开发活动，化学优化/开发，GMP制造以及临床安全性和有效性评估。